Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology

The practice of radiation oncology is primarily based on precise technical delivery of highly conformal, image-guided external beam radiotherapy or brachytherapy. However, systematic research efforts are being made to facilitate individualised radiation dose prescriptions on the basis of gene-expres...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2018-05, Vol.19 (5), p.e240-e251
Main Authors: Bristow, Robert G, Alexander, Brian, Baumann, Michael, Bratman, Scott V, Brown, J Martin, Camphausen, Kevin, Choyke, Peter, Citrin, Deborah, Contessa, Joseph N, Dicker, Adam, Kirsch, David G, Krause, Mechthild, Le, Quynh-Thu, Milosevic, Michael, Morris, Zachary S, Sarkaria, Jann N, Sondel, Paul M, Tran, Phuoc T, Wilson, George D, Willers, Henning, Wong, Rebecca K S, Harari, Paul M
Format: Article
Language:English
Subjects:
Brachytherapy
Cancer
Cancer therapies
Chemotherapy
Clinical trials
Drug dosages
Immunomodulation
Immunotherapy
Medical research
Metastasis
Microenvironments
Mutation
Patients
Radiation therapy
Radiosensitivity
Solid tumors
Tumor microenvironment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The practice of radiation oncology is primarily based on precise technical delivery of highly conformal, image-guided external beam radiotherapy or brachytherapy. However, systematic research efforts are being made to facilitate individualised radiation dose prescriptions on the basis of gene-expressssion profiles that reflect the radiosensitivity of tumour and normal tissue. This advance in precision radiotherapy should complement those benefits made in precision cancer medicine that use molecularly targeted agents and immunotherapies. The personalisation of cancer therapy, predicated largely on genomic interrogation, is facilitating the selection of therapies that are directed against driver mutations, aberrant cell signalling, tumour microenvironments, and genetic susceptibilities. With the increasing technical power of radiotherapy to safely increase local tumour control for many solid tumours, it is an opportune time to rigorously explore the potential benefits of combining radiotherapy with molecular targeted agents and immunotherapies to increase cancer survival outcomes. This theme provides the basis and foundation for this American Society for Radiation Oncology guideline on combining radiotherapy with molecular targeting and immunotherapy agents.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(18)30096-2